Moderna Added to Nasdaq-100 Index, Impact on Investors
Pharmaceutical company Moderna (ticker: MRNA) has been added to the Nasdaq-100 index. This inclusion means that ETFs tracking this index will need to purchase shares of Moderna in order to align with its composition. One such fund is Invesco QQQ Trust, which now holds approximately $2 billion worth of Moderna stock—representing more than 2% of the company's market cap. The addition could increase demand for MRNA as institutional investors acquire and hold shares over a longer period, potentially making it harder and costlier for individual investors to purchase. While this is not the primary reason to invest in Moderna, its recent performance has been driven by promising developments such as phase 3 trial results of its cancer vaccine intismeran autogene combined with Merck's Keytruda, along with FDA approvals for updated vaccines against COVID-19 and influenza. Moderna’s stock price surged over 700% this year due to these factors, contributing significantly to the company qualifying for inclusion in the Nasdaq-100. This milestone reflects growing investor confidence and broader recognition of Moderna's potential.
Topics: ETFs Moderna Nasdaq-100 Index pharmaceutical industry